Hillhouse-backed cancer drug maker InnoCare moves closer to $620m STAR Market listing

InnoCare Pharma, a Chinese cancer drug developer backed by the Asian private equity (PE) major Hillhouse Capital Group, has moved closer to a planned secondary listing on Shanghai’s Nasdaq-style STAR Market that could raise about 4 billion yuan ($620.4 million).